---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-23-000037"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T09:49:29.588845+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edwards Q3 sales $1.48B (+12%), EPS $0.63; TAVR grows 11%; guidance reaffirmed

## Summary
- Q3 revenue $1.48B (+12% reported, +11% constant currency); GAAP EPS $0.63, adjusted EPS $0.59.
- TAVR sales $961M (+11%); TMTT sales $52M on PASCAL Precision adoption; Surgical $247M (+12%).
- Adjusted gross margin 76.4% vs 81.0% a year ago on FX headwinds; FY2023 guidance reaffirmed (10-13% CC sales growth, adj. EPS $2.50-$2.60).
- Regulatory milestones: EVOQUE CE Mark (first transfemoral tricuspid replacement), PASCAL Precision approved in Japan, SAPIEN M3 pivotal trial enrollment completed.
- Free cash flow $356M; $174M share repurchased in Q3; cash & short-term investments $1.9B.

## SEC filing metadata
- accession: 0001099800-23-000037
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000037/0001099800-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000037/ew-20231025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-23-000037
- JSON: https://secwatch.observer/filing/0001099800-23-000037.json
- Plain text: https://secwatch.observer/filing/0001099800-23-000037.txt

## Key facts
- Earnings Releases
  Edwards Lifesciences Corp reported the quarter ended Sept. 30, 2023 results: revenue $1.48 billion, EPS $0.63. Guidance reaffirmed.
  - Period: the quarter ended Sept. 30, 2023
  - Revenue: $1.48 billion
  - EPS: $0.63
  - Guidance: reaffirmed
  - Result: reported results
  source text: 25, 2023 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook • Q3 sales grew 12 percent to $1.48 billion; constant currency 1 sales grew 11 percent • Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent • Q3 EPS of $0.63; adjusted 1 EPS of $0.59 • Received CE Mark
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000037/0001099800-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.